MKGAF Stock UPDATES Merck Kgaa Dm 5 (MKGAF) 86.8600 10/22/2014
Post# of 273217
Sigma-Aldrich Offers Ascentis Express 2.0 Micron UHPLC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 3:00PM CDT
Sigma-Aldrich (SIAL) has launched Ascentis Express 2.0 micron built on Fused-Core particle design.
SIAL: 135.85 (+0.25), TROX: 22.61 (-0.69), FSI: 1.17 (-0.08)
Sigma-Aldrich to Acquire Cell Marque to Bolster IHC Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 11:30AM CDT
Sigma-Aldrich Corporation (SIAL) announced that it has agreed acquire Cell Marque Corporation in order to strengthen its diagnostic health capabilities.
GSM: 17.85 (-0.16), SIAL: 135.85 (+0.25), FSI: 1.17 (-0.08)
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 63.19 (-0.54), BMRN: 74.32 (-0.39), AMGN: 143.64 (-0.45)
Merck KGaA Records the Largest Acquisition in Their History at $17 Billion (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 8:00AM CDT
Merck KGaA (MKGAF) will acquire Sigma-Aldrich for $17 billion, or $140 per share in cash.
SIAL: 135.85 (+0.25)
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 309.07 (-17.70), GILD: 106.09 (-0.58), RGDO: 1.13 (-0.02)
Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 6:00PM CDT
Merck KGaA's (MKGAF) signed a collaboration and license agreement with Sutro Biopharma to develop antibody drug conjugates (ADCs) targeting cancer cells.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), SGEN: 34.83 (-0.48)
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), ANAC: 27.66 (-0.58)
Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 44.72 (-0.24), AVNR: 11.66 (-0.13), ANAC: 27.66 (-0.58)
Merck KGaA's Kuvan Effective in Under-4 Year Olds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:35PM CDT
Merck KGaA (MKGAF) announced that Kuvan showed statistically significant 26-week data from the phase IIIb SPARK study in children (<4 years) with phenylketonuria.
LCI: 44.72 (-0.24), ENDP: 63.19 (-0.54), BMRN: 74.32 (-0.39)
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
AGN: 182.81 (-3.35), MNK: 87.10 (-2.20), ENDP: 63.19 (-0.54)
Merck KGaA Q2 Earnings Slip Y/Y, 2014 Sales View Confirmed - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 15, 8:00AM CDT
Merck KGaA's (MKGAF) second-quarter 2014 earnings per American Depositary Receipt (ADR) came in at $1.52, down 1.8% from the year-ago quarter.
ENDP: 63.19 (-0.54), UTHR: 129.00 (+1.39), ANAC: 27.66 (-0.58)
Roche Collaborates with Merck KGaA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 5:30PM CDT
Roche's (RHHBY) Ventana Medical Systems announced that it has entered into an agreement with Germany-based Merck KGaA.
AZN: 68.78 (-0.22), ABBV: 56.90 (+0.61)
Merck KGaA-Mersana Therapeutics Strike a Deal on ADCs - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jun 24, 4:20PM CDT
Merck KGaA (MKGAF) inked a deal with Mersana Therapeutics for the development of next-generation antibody-drug conjugates (ADCs) for the treatment of cancer.
SGEN: 34.83 (-0.48), ARIA: 5.59 (-0.20)
Merck KGaA-Ono Pharma Deal Ends - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 5:15PM CDT
Merck KGaA (MKGAF) has decided to terminate its license agreement with Ono Pharma related to the development of Ono Pharma's multiple sclerosis candidate, ceralifimod (ONO-4641).
GILD: 106.09 (-0.58), ARIA: 5.59 (-0.20)
Merck KGaA & MorphoSys Sign Deal, Immuno-Oncology in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 12, 3:30PM CDT
Merck KGaA (MKGAF) and MorphoSys inked a deal to discover and develop therapeutic antibodies against undisclosed immune checkpoints.
ANIP: 27.93 (-0.16), INCY: 52.47 (+0.03), AZN: 68.78 (-0.22)
Merck KGaA/Auxogyn's Eeva System Gets FDA Clearance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 3:40PM CDT
Merck KGaA's (MKGAF) biopharma division, Merck Serono, announced that the FDA has granted clearance to Merck KGaA and partner Auxogyn's Early Embryo Viability Assessment (Eeva) System.
Q: 56.55 (+0.05), GILD: 106.09 (-0.58), ANIP: 27.93 (-0.16)
Merck KGaA Enrolls First Patient in Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 1:28PM CDT
Merck KGaA enrolled the first patient in a phase III study (ESPART) on Pergoveris
LCI: 44.72 (-0.24), ACT: 231.41 (-0.72), SLXP: 137.61 (-2.94)
Merck KGaA Misses 2013 Earnings & Rev Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Mar 07, 9:30AM CST
Merck KGaA reported 2013 earnings per ADR of $11.70, up 19.2% year over year but below the Zacks Consensus Estimate of $11.99.
LCI: 44.72 (-0.24), ACT: 231.41 (-0.72), FRX: 99.00 (-0.77)
Avanir Reports Narrower Loss, Revs Up Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 06, 11:40AM CST
Avanir Pharma reported first quarter fiscal 2014 net loss per share of 7 cents, narrower than the Zacks Consensus Estimate of a loss of 8 cents
ECYT: 5.63 (+0.05), AVNR: 11.66 (-0.13), BIOD: 1.39 (-0.05)
Threshold Pharma's TH-302 in Melanoma Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 15, 12:00PM CDT
Threshold Pharmaceuticals recently initiated a phase II trial on its pipeline candidate, TH-302.
BIIB: 309.07 (-17.70), THLD: 2.97 (-0.03), LLY: 64.68 (unch)